
Medha Joshi, Medha D Joshi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2528703/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Course design, delivery, and assessment strategies for pharmaceutical calculations course in a doctor of pharmacy program: A review. Currents in Pharmacy Teaching and Learning, 2022, 14, 526-535.	0.4	3
2	Vancomycin Pharmacokinetics in a Pregnancy Rat Model. Antimicrobial Agents and Chemotherapy, 2022, 66, e0005622.	1.4	1
3	In Vitro Nephrotoxicity and Permeation of Vancomycin Hydrochloride Loaded Liposomes. Pharmaceutics, 2022, 14, 1153.	2.0	4
4	Pharmacokinetic Disposition of Amiodarone When Given with an Intralipid Rescue Strategy. Pharmaceutics, 2021, 13, 539.	2.0	0
5	An Online, Self-directed Pharmacy Bridging Course for Incoming First-Year Students. American Journal of Pharmaceutical Education, 2020, 84, ajpe7684.	0.7	1
6	Evaluation of Fetal and Maternal Vancomycin-Induced Kidney Injury during Pregnancy in a Rat Model. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	5
7	Fabrication of Nanostructured Lipid Carriers (NLC)-Based Gels from Microemulsion Template for Delivery Through Skin. Methods in Molecular Biology, 2019, 2000, 279-292.	0.4	11
8	Twenty-four hour pharmacokinetic relationships for intravenous vancomycin and novel urinary biomarkers of acute kidney injury in a rat model. Journal of Antimicrobial Chemotherapy, 2019, 74, 2326-2334.	1.3	41
9	A Translational Pharmacokinetic Rat Model of Cerebral Spinal Fluid and Plasma Concentrations of Cefepime. MSphere, 2019, 4, .	1.3	4
10	Towards long-acting adrenaline for cardiopulmonary resuscitation: Production and characterization of a liposomal formulation. International Journal of Pharmaceutics, 2019, 557, 105-111.	2.6	4
11	Dose, duration, and animal sex predict vancomycin-associated acute kidney injury in preclinical studies. International Journal of Antimicrobial Agents, 2018, 51, 239-243.	1.1	20
12	1419. 24-Hour Pharmacokinetic Relationships for Intravenous Vancomycin and Novel Urinary Biomarkers of Acute Kidney Injury. Open Forum Infectious Diseases, 2018, 5, S437-S438.	0.4	0
13	1394. A Translational Pharmacokinetic Rat Model of Cerebral Spinal Fluid (CSF) and Plasma Concentrations of Cefepime. Open Forum Infectious Diseases, 2018, 5, S429-S429.	0.4	0
14	Highâ€Performance Liquid Chromatography Method for Rich Pharmacokinetic Sampling Schemes in Translational Rat Toxicity Models With Vancomycin. Clinical and Translational Science, 2017, 10, 496-502.	1.5	11
15	24-Hour Pharmacokinetic Relationships for Vancomycin and Novel Urinary Biomarkers of Acute Kidney Injury. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	39
16	In Vitro Evaluation of Bortezomib Encapsulated in Cationic and C6-Ceramide Liposomes. Journal of Pharmaceutical Sciences and Pharmacology, 2017, 3, 146-154.	0.2	3
17	Drug delivery during pregnancy: how can nanomedicine be used?. Therapeutic Delivery, 2017, 8, 1023-1025.	1.2	14
18	Evaluation of liposomal nanocarriers loaded with ETB receptor agonist, IRL-1620, using cell-based assays. Neuroscience, 2016, 312, 141-152.	1.1	10

#	Article	IF	CITATIONS
19	Polymeric nanoparticles for targeted treatment in oncology: current insights. International Journal of Nanomedicine, 2015, 10, 1001.	3.3	223
20	Resolvin D1 activates the inflammation resolving response at splenic and ventricular site following myocardial infarction leading to improved ventricular function. Journal of Molecular and Cellular Cardiology, 2015, 84, 24-35.	0.9	194
21	Peptide Vaccine: Progress and Challenges. Vaccines, 2014, 2, 515-536.	2.1	518
22	Nanocarrier-Based Approaches for Treatment and Detection of Alzheimer's Disease. Journal of Nanoscience and Nanotechnology, 2014, 14, 137-156.	0.9	22
23	Parasite impairment by targeting Plasmodium-infected RBCs using glyceryl-dilaurate nanostructured lipid carriers. Biomaterials, 2014, 35, 6636-6645.	5.7	28
24	Research Highlights: Highlights from the latest articles in nanomedicine. Nanomedicine, 2013, 8, 169-171.	1.7	0
25	Nanomedicines for Treatment of Viral Diseases. Critical Reviews in Therapeutic Drug Carrier Systems, 2013, 30, 1-49.	1.2	32
26	Encapsulation in ceramide lipid nanoparticles enhances bortezomibâ€induced effects on metabolic activity. FASEB Journal, 2013, 27, 893.6.	0.2	0
27	Targeted delivery of camptothecin to the brain using solid lipid nanoparticles. Nanomedicine, 2013, 8, 169-70.	1.7	0
28	Liver targeting using cationic solid lipid nanoparticles derived from apolipoprotein-free low-density lipoprotein. Nanomedicine, 2013, 8, 170.	1.7	0
29	Surface-modified polymeric nanoparticles for targeted delivery to glioblastoma. Nanomedicine, 2013, 8, 170-1.	1.7	1
30	Intracellular delivery of liposomes using cell-penetrating peptides. Nanomedicine, 2013, 8, 171.	1.7	0
31	Antigen-expressing immunostimulatory liposomes for induction of immunity. Nanomedicine, 2013, 8, 171.	1.7	0
32	Nanocarriers for Effective Topical Delivery of Anti-Infectives. Current Nanoscience, 2012, 8, 491-503.	0.7	21
33	Intravenous Â-artemether formulation (ARM NLC) as a superior alternative to commercial artesunate formulation. Journal of Antimicrobial Chemotherapy, 2012, 67, 2713-2716.	1.3	13
34	Glycan-modified liposomes boost CD4+ and CD8+ T-cell responses by targeting DC-SIGN on dendritic cells. Journal of Controlled Release, 2012, 160, 88-95.	4.8	158
35	Targeting tumor antigens to dendritic cells using particulate carriers. Journal of Controlled Release, 2012, 161, 25-37.	4.8	174
36	DC-SIGN mediated antigen-targeting using glycan-modified liposomes: Formulation considerations. International Journal of Pharmaceutics, 2011, 416, 426-432.	2.6	33

#	Article	IF	CITATIONS
37	Nanocarriers for Imaging Applications. Surfactant Science, 2010, , 563-611.	0.0	1
38	Biocompatible Microemulsions for Fabrication of Glyceryl Monostearate Solid Lipid Nanoparticles (SLN) of Tretinoin. Journal of Biomedical Nanotechnology, 2009, 5, 396-400.	0.5	34
39	Lipid nanoparticles for parenteral delivery of actives. European Journal of Pharmaceutics and Biopharmaceutics, 2009, 71, 161-172.	2.0	388
40	Nanostructured lipid carrier (NLC) based gel of celecoxib. International Journal of Pharmaceutics, 2008, 346, 124-132.	2.6	247
41	Solid microemulsion preconcentrate (NanOsorb) of artemether for effective treatment of malaria. International Journal of Pharmaceutics, 2008, 362, 172-178.	2.6	61
42	Design and in vivo pharmacodynamic evaluation of nanostructured lipid carriers for parenteral delivery of artemether: Nanoject. International Journal of Pharmaceutics, 2008, 364, 119-126.	2.6	150
43	Solid lipid nanoparticles (SLN) of tretinoin: Potential in topical delivery. International Journal of Pharmaceutics, 2007, 345, 163-171.	2.6	304
44	Parasitic diseases: Liposomes and polymeric nanoparticles versus lipid nanoparticlesâ~†. Advanced Drug Delivery Reviews, 2007, 59, 505-521.	6.6	248
45	Formulation and Evaluation of Nanostructured Lipid Carrier (NLC)–based Gel of Valdecoxib. Drug Development and Industrial Pharmacy, 2006, 32, 911-918.	0.9	178